유전자형 분석 시장 규모, 점유율, 성장 분석 : 제품별, 기술별, 용도별, 최종 용도별, 지역별 - 업계 예측(2026-2033년)

Genotyping Market size was valued at USD 18.29 Billion in 2024 and is poised to grow from USD 20.52 Billion in 2025 to USD 51.54 Billion by 2033, growing at a CAGR of 12.2% during the forecast period (2026-2033).

The global genotyping market is witnessing significant expansion, propelled by innovations in genomics, personalized medicine, and a heightened demand for genetic testing. This growth is largely driven by an increasing incidence of genetic disorders, greater public awareness regarding early disease detection, and advances in precision medicine. Various genotyping technologies, such as microarrays, polymerase chain reaction (PCR), and next-generation sequencing (NGS), are extensively utilized across both research and clinical applications. Furthermore, the synergy between genotyping data and bioinformatics, along with data analytics, is contributing to the market's upward trajectory. The competitive landscape features major players prioritizing product innovation, enlarging their genetic testing offerings, and forging strategic partnerships to enhance their market presence.

Top-down and bottom-up approaches were used to estimate and validate the size of the Genotyping market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Genotyping Market Segments Analysis

Global Genotyping Market is segmented by Product, Technology, Application, End-use and region. Based on Product, the market is segmented into Instruments, Reagents & Kits and Software and Services. Based on Technology, the market is segmented into PCR, Capillary Electrophoresis, Microarrays, Sequencing, Mass Spectrometry and Others. Based on Application, the market is segmented into Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics and Others. Based on End-use, the market is segmented into Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, Academic Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Genotyping Market

A significant factor propelling the genotyping market is the heightened occurrence of genetic disorders alongside an increasing interest in personalized medicine. Genotyping is essential for detecting genetic variations, mutations, and gene sequences that correlate with particular illnesses or responses to treatments. As genomic research advances and our comprehension of genetic markers deepens, genotyping facilitates tailored diagnosis, treatment strategies, and drug selection. The combination of a growing incidence of genetic disorders and the movement towards precision medicine drives the rising demand for genotyping technologies and services. This trend underscores the critical role of genotyping in modern healthcare.

Restraints in the Genotyping Market

The global genotyping market faces notable challenges primarily stemming from ethical and privacy issues linked to genetic testing. The ability to access personal genetic data raises significant concerns regarding potential misuse or misinterpretation. Issues surrounding informed consent, data security, and the risk of discrimination based on genetic information hinder broader acceptance and application of genotyping. Additionally, the proper communication and interpretation of genetic test results demand meticulous attention to ensure clarity and guide appropriate responses from individuals and healthcare providers. Tackling these ethical and privacy dilemmas is essential to foster trust, enhance participation, and ensure the responsible implementation of genotyping technologies.

Market Trends of the Genotyping Market

The Genotyping market is witnessing a significant shift toward personalized medicine and precision healthcare, fundamentally transforming patient treatment approaches. As the understanding of genetic variations and their link to disease progression and drug efficacy deepens, the demand for genotyping technologies rises correspondingly. The advances in genomic technologies and their consequent reduction in costs are democratizing access for healthcare professionals and researchers alike. This evolution facilitates the development of individualized treatment regimens tailored to each patient's genetic profile, enhancing therapeutic efficacy and disease management. As a result, genotyping is emerging as a cornerstone of modern healthcare, fostering targeted interventions and optimizing patient outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Technology Analysis

Global Genotyping Market Size by Product & CAGR (2026-2033)

• Market Overview
• Instruments
• Reagents & Kits
• Software and Services

Global Genotyping Market Size by Technology & CAGR (2026-2033)

• Market Overview
• PCR
• Capillary Electrophoresis
• Microarrays
• Sequencing
• Mass Spectrometry
• Others

Global Genotyping Market Size by Application & CAGR (2026-2033)

• Market Overview
• Pharmacogenomics
• Diagnostics and Personalized Medicine
• Agricultural Biotechnology
• Animal Genetics
• Others

Global Genotyping Market Size by End-use & CAGR (2026-2033)

• Market Overview
• Pharmaceutical and Biopharmaceutical Companies
• Diagnostics and Research Laboratories
• Academic Institutes
• Others

Global Genotyping Market Size & CAGR (2026-2033)

• North America (Product, Technology, Application, End-use)
  • US
  • Canada
• Europe (Product, Technology, Application, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Technology, Application, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Technology, Application, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Technology, Application, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Thermo Fisher Scientific Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fluidigm Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacific Biosciences of California, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Nanopore Technologies Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations